Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical Trial

REFERENCES

• Rowe J. M., Andersen J. W., Mazza J. J., Bennett J. M., Paietta E., Hayes F. A., Oette D., Cassileth P. A., Stadtmauer E. A., Wiernik P. H. A Randomized Placebo-Controlled Phase III Study of Granulocyte Macrophage Colony Stimulating Factor in Adult Patients (>55 to 70 Years of Age) with Acute Myelogenous Leukemia: A Study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457–462
   PubMed Web of Science ®Google Scholar
• Heil G., Hoelzer D., Sanz M. A., Lechner K., Liu Yin J. A., Papa G., Noens L., Szer J., Ganser A., O'Brien C., Matcham J., Barge A. A Randomized Double-Blind Placebo-Controlled Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults with De Novo Acute Myeloid Leukemia. Blood 1997; 90: 4710–4718
   PubMed Web of Science ®Google Scholar
• Stone R. M., Berg D. T., George S. L., Dodge R. K., Paciucci P. A., Schulman P., Lee E. J., Moore J. O., Powell B. L., Schiffer C. A. Granulocyte-Macrophage Colony-Stimulating Factor After Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia. Cancer and Leukemia Group B. N. Engl. J. Med. 1995; 332: 1671–1675
   PubMed Web of Science ®Google Scholar
• Lowenberg B., Suciu S., Zittoun R., et al. Granulocyte Macrophage Colony Stimulating Factor During as Well as After Induction Chemotherapy in Elderly Patients with Acute Myeloid Leukemia. The EORTC-HOVON Phase III Trial (AML 11). Blood 1995; 86(suppl 1)433a
   Google Scholar
• Witz F., Sadoun A., Perrin M. C., Berthou C., Briere J., Cahn J. Y., Lioure B., Witz B., Francois S., Desablens B., Pignon B., Le Prise P. Y., Audhuy B., Caillot D., Casassus P., Delain M., Christian B., Tellier Z., Polin V., Hurteloup P., Harousseau J. L. A Placebo Controlled Study of Recombinant Human Granulocyte Macrophage Colony Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myeloid Leukemia in Elderly Patients. Blood 1998; 91(8)2722–2730
   PubMed Web of Science ®Google Scholar
• Zittoun R., Suciu S., Mandelli F., de Witte T., Thaler J., Stryckmans P., Hayat M., Peetermans M., Cadiou M., Solbu G., Petti M. C., Willemze R. Granulocyte Macrophage Colony Stimulating Factor Associated with Induction Treatment of Acute Myelogenous Leukemia: A Randomized Trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J. Clin. Oncol. 1996; 14: 2150–2159
   PubMed Web of Science ®Google Scholar
• Godwin J. E., Kopecky K., Head D. R., Hynes H. E., Balcerzak S. P., Appelbaum F. R. A Double-Blind Placebo-Controlled Trial of Granulocyte Colony Stimulating Factor in Elderly Patients with Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study. Blood 1998; 91(10)3607–3615
   PubMed Web of Science ®Google Scholar
• Dombret H., Chastang C., Fenaux P., Reiffers J., Bordessoule D., Bouabdallah R., Mandelli F., Ferrant A., Auzanneau G., Tilly H., Yver A., Degos L. A Controlled Study of Recombinant Human Granulocyte Colony Stimulating Factor in Elderly Patients After Treatment for Acute Myelogenous Leukemia. N. Engl. J. Med. 1995; 332: 1678–1683
   PubMed Web of Science ®Google Scholar
• Ohno R., Tomonga M., Kobayashi T., Kanamaru A., Shirakawa S., Masaoka T., Omine M., Oh H., Nomura T., Sakai Y. Effect of Granulocyte Colony Stimulating Factor After Induction Therapy in Relapsed or Refractory Leukemia. N. Engl. J. Med. 1990; 323: 871–876
   PubMed Web of Science ®Google Scholar
• Heil G., Chadid L., Hoelzer D., Seipelt G., Mitrou P., Huber C., Kolbe K., Mertelsmann R., Lindemann A., Frisch J. Granulocyte Macrophage Colony Stimulating Factor in a Double-Blind Randomized Placebo-Controlled Trial in Therapy in Adult Patients with De Novo Acute Myeloid Leukemia. Leukemia 1995; 5: 3–8
   Google Scholar
• Rowe J. M., Rubin A., Mazza J. J., Bennett J. M., Paietta E., Anderson J. W., Ghalie R., Wiernick P. H. Incidence of Infections in Adult Patients (>55 Years) with Acute Myeloid Leukemia Treated with Yeast Derived GM-CSF: Results of a Double-Blind Prospective Study by the Eastern Cooperative Oncology Group. Acute Leukemias V: Experimental Approaches and Management of Refractory Diseases, W. Hiddeman, T. Buchner, B. Wormann, J. Ritter, U. Creutzig, W. Plunkett, M. Keating. Springer-Verlag, Berlin 1996
   Google Scholar
• The American Society of Clinical Oncology. Update of Recommendations for the Use of Hematopoietic Colony Stimulating Factors: Evidence-Based Clinical Practice Guidelines. J. Clin. Oncol. 1996; 14: 1957–1960
   PubMed Web of Science ®Google Scholar
• The American Society of Clinical Oncology. American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Growth Factors: Evidence Based Clinical Practice Guidelines. J. Clin. Oncol. 1994; 12: 2471–2508
   PubMed Web of Science ®Google Scholar
• Lu Z. J., Luo R., Erder H., Heil G., Ganser A., Lechner K., Yin J. L., Szer J., Barge A. Cost Impact of Filgrastim as an Adjunct to Chemotherapy for Patients with Acute Myeloid Leukemia. Blood 1996; 88((suppl 1) 10)826
   Web of Science ®Google Scholar
• Bennett C. L., Golub R., Waters T. M., Tallman M. S., Rowe J. M. Economic Analyses of Phase III Cooperative Cancer Group Clinical Trials: Are They Feasible?. Cancer Invest 1997; 15: 227–236
   PubMed Web of Science ®Google Scholar
• Pui C-H., Boyett J. M., Hughes W. T., Rivera G. K., Hancock M. L., Sandlund J. T., Synold T., Relling M. V., Ribeiro R. C., Crist W. M., Evans W. E. Human Granulocyte Colony Stimulating Factor After Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. N. Engl. J. Med. 1997; 336: 1781–1787
   PubMed Web of Science ®Google Scholar
• Bennett C. L., Stinson T. J., Lane D., Amylon M., Land V., Laver J. A Cost-Analysis of Filgrastim for the Prevention of Neutropenia in Pediatric T-Cell Leukemia and Advanced Lymphoblastic Lymphoma. Med. Pediatr. Oncol. 2000; 34(2)92–96
   PubMedGoogle Scholar
• Bennett C. L., Stinson T. J., Tallman M. S., Stadtmauer E. A., Marsh R. M., Friedenberg W., Lazarus H. M., Kaminer L., Golub R. M., Rowe J. M. Economic Analysis of a Randomized, Placebo-Controlled Phase III Study of Granulocyte Macrophage Colony Stimulating Factor in Adult Patients with Acute Myelogenous Leukemia. Ann. Oncol. 1999; 10: 177–182
   PubMed Web of Science ®Google Scholar
• Woronoff-Lemsi M. C., Demoly P., Arveux P., Ifrah N., Tellier Z., Harousseau J. L., Cahn J. Y., Witz F. Cost-Effectiveness Analysis of GOELAM SA3, a Randomized Placebo-Controlled Protocol of GM-CSF for Elderly Patients with Acute Myeloid Leukemia. Blood 1997; 90((suppl 1) 10)313–I
   PubMed Web of Science ®Google Scholar
• Bennett C. L., Waters T. M. Economic Analyses in Clinical Trials for Cooperative Groups: Operational Considerations. Cancer Invest 1997; 15: 448–453
   PubMed Web of Science ®Google Scholar
• Bennett C. L., Bishop M. R., Tallman M. S., Somerfield M. R., Feinglass J., Smith T. J. The Association Between Physician Reimbursement in the US and Use of Hematopoietic Colony Stimulating Factors as Adjunct Therapy for Older Patients with Acute Myeloid Leukemia: Results from the 1997 American Society of Clinical Oncology Survey. Ann. Oncol. 1999; 10: 1–5
   Google Scholar